No Stock Yet
The pharmaceutical sector rushed in early trading, what happened? Pay attention to these opportunities in the future
The agency said that at present, the valuation of the pharmaceutical industry is low, there is much room for improvement, and the value of plate allocation is prominent; in terms of investment strategy, it is recommended to pay attention to the upstream track of consumer health care and life sciences, and to focus on the creation of new drug track at the bottom.
New inactivated crown vaccine approved for children aged 6 months and above for the first time
Deutsche Bank: the target price for CSPC Pharmaceutical's (01093) "buy" rating is HK $11.80.
Zhitong Financial APP learned that Deutsche Bank released a research report saying it first gave CSPC Pharmaceutical a "buy" rating of 01093, with a target price of HK $11.80. As a leading pharmaceutical company in China, it focuses on developing, manufacturing and selling innovative drugs, generics and APIs. Most of the company's existing flagship products, such as NBP, Xuanning and Domesu, accounted for more than 50% of total revenue last year and are drugs that have been launched for more than a decade. The bank expects that the new products may become new catalysts for the company's share price, such as DUOENDA and irinotecan liposome injection (Irinotecan lip).
Hong Kong anti-epidemic concept stocks continue to decline
Pride and Prejudice of innovative drugs: talking about "License-in" in controversy
CSPC Pharmaceutical (01093.HK): independent non-executive director Wu Guizhen resigned
CSPC Pharmaceutical (01093.HK) announced that Wu Guizhen has resigned as an independent non-executive director of the company due to her personal work arrangement, effective from August 1st, 2022.
CSPC Pharmaceutical (01093): Wu Guizhen resigned as independent non-executive director
Zhitong Financial APP News, CSPC Pharmaceutical (01093) announced that Wu Guizhen resigned as an independent non-executive director of the company due to her personal work arrangements, effective from August 1st, 2022.
Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$11.14 From HK$11.20, Keeps at Buy
05:51 AM EDT, 08/01/2022 (MT Newswires) --
US FDA Grants Orphan Drug Status to CSPC Pharmaceutical's Gastric Cancer Injection
02:00 AM EDT, 07/29/2022 (MT Newswires) -- The US Food and Drug Administration granted orphan drug status to CSPC Pharmaceutical Group's (HKG:1093) docetaxel for injection for the treatment of gastric
Elevation Oncology to license an antibody drug conjugate from China's CSPC Pharma
Elevation Oncology (NASDAQ:ELEV) on Thursday said it would give an upfront payment of $27M to CSPC Megalith Biopharmaceutical to license antibody drug conjugate EO-3021. ELEV stock was down 14.2% to $
No Stock Yet